Cardiovascular MRI in thalassemia major

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 173-179

  Wood, John C ^a   Noetzli, Leila ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

heart; iron; MRI; thalassemia

Indexed keywords

IRON;

CARDIOMYOPATHY; CARDIOTOXICITY; CHELATION THERAPY; CONFERENCE PAPER; HEART FUNCTION; HEART MUSCLE; HEART VENTRICLE FUNCTION; HUMAN; IRON CHELATION; NUCLEAR MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY; THALASSEMIA MAJOR;

EID: 77955902348     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05571.x     Document Type: Conference Paper

References (40)

1. Ehlers, K.H., A.R. Levin, A.L.Markenson, et al. 1980. Longitudinal study of cardiac function in thalassemiamajor. Ann. N.Y. Acad. Sci. 344: 397-404.
2. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 2004. Survival and complications in patients with thalassemiamajor treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
3. Olivieri, N.F., D.G. Nathan, J.H.MacMillan, et al. 1994. Survival in medically treated patients with homozygous betathalassemia. N. Engl. J. Med. 331: 574-578.
4. Brittenham, G.M., P.M. Griffith, A.W. Nienhuis, et al. 1994. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemiamajor. N. Engl. J.Med. 331: 567-573.
5. Anderson, L.J.,M.A.Westwood, E. Prescott, et al. 2006. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 115: 106-108.
6. Noetzli, L.J., S.M. Carson, A.S. Nord, et al. 2008. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 112: 2973-2978.
7. Kremastinos, D.T., G. Tiniakos, G.N. Theodorakis, et al. 1995.Myocarditis in beta-thalassemiamajor: a cause of heart failure. Circulation 91: 66-71.
8. Anderson, L.J., S.Holden, B.Davis, et al. 2001. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22: 2171-2179.
9. Wood, J.C., J.M. Tyszka, N. Ghugre, et al. 2004. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 103: 1934-1936.
10. Westwood, M.A., L.J. Anderson, A.M. Maceira, et al. 2007. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J. Magn. Reson. Imaging 25: 1147-1151.
11. Anderson, L.J., M.A. Westwood, S. Holden, et al. 2004. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. 127: 348-355.
12. Fischer, R., & R. Engelhardt. 2003. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 361: 182-183; author reply 183-184.
13. St Pierre, T.G. 2003. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 361: 182; author reply 183-184.
14. Wood, J.C., M. Otto-Duessel, M.Aguilar, et al. 2005. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112: 535-543.
15. Ghugre, N., C. Enriquez & J.C.Wood. 2005. Myocardial R2 and R2* vary linearly with cardiac iron in human heart. In Paper presented at the International Society of Magnetic Resonance in Medicine, Miami Beach, FL.
16. Wood, J.C., C. Enriquez, N. Ghugre, et al. 2005. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106: 1460-1465.
17. Hankins, J.S., McCarville, M.B., Loeffler, R.B., et al. 2009. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113: 4853-4855.
18. Noetzli, L.J., J. Papudesi, T.D. Coates & J.C. Wood. 2009. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 114: 4021-4026.
19. Wood, J.C., R. Origa, A. Agus, et al. 2008. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 93: 917-920.
20. Gabutti, V. & C. Borgna-Pignatti. 1994. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin. Haematol. 7: 919-940.
21. Wood, J.C., J. Fassler & T. Meade. 2004. Mimicking liver iron overload using liposomal ferritin preparations. Mag Res Med. 51: 607-611.
22. Davis, B.A., C. O'Sullivan, P.H. Jarritt & J.B. Porter. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269.
23. Kirk, P., M. Roughton, J.B. Porter, et al. 2009. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120: 1961-1968.
24. Westwood, M., L.J. Anderson, D.N. Firmin, et al. 2003. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J. Magn. Reson. Imaging. 18: 33-39.
25. Westwood, M.A., D.N. Firmin, M. Gildo, et al. 2005. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int. J. Cardiovasc. Imaging 21: 531-538.
26. Tanner, M.A., T. He, M.A. Westwood, et al. 2006. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 91: 1388-1391.
27. He, T., P.D. Gatehouse, P. Kirk, et al. 2007. Black-blood T2* technique for myocardial iron measurement in thalassemia. J. Magn. Reson. Imaging 25: 1205-1209.
28. Mavrogeni, S.I., T.Maris, A. Gouliamos, et al. 1998.Myocardial iron deposition in beta-thalassemia studied by magnetic resonance imaging. Int. J. Card. Imaging 14: 117-122.
29. Voskaridou, E., M. Douskou, E. Terpos, et al. 2004.Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br. J. Haematol. 126: 736-742.
30. Papakonstantinou, O., E. Alexopoulou, N. Economopoulos, et al. 2009. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with betathalassemia major. J. Magn. Reson. Imaging 29: 853-859.
31. He, T., P. Kirk, D.N. Firmin, et al. 2008. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J. Cardiovasc. Magn. Reson. 10: 11.
32. Guo, H., W.Y. Au, J.S. Cheung, et al. 2009. Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J. Magn. Reson. Imaging 30: 394-400.
33. He, T., P.D. Gatehouse, P. Kirk, et al. 2008. Myocardial T(*)2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn. Reson. Med. 60: 350-356.
34. He, T., P.D. Gatehouse, G.C. Smith, et al. 2008. Myocardial T2* measurements in iron-overloaded thalassemia: an in vivo study to investigate optimal methods of quantification. Magn. Reson. Med. 60: 1082-1089.
35. Clark, P.R., W. Chua-anusorn & T.G. St Pierre. 2003. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. Magn. Reson. Imaging 21: 519-530.
36. Ghugre, N., C. Enriquez, T.D. Coates, et al. 2005. Improved R2* Measurements in Myocardial Iron Overload. J. Cardiovasc. Magn. Reson. 7: 32-33.
37. Ghugre, N.R., C.M. Enriquez, T.D. Coates, et al. 2006. Improved R2* measurements in myocardial iron overload. J. Magn. Reson. Imaging 23: 9-16.
38. Pepe, A., V. Positano, M.F. Santarelli, et al. 2006. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution ofmyocardial iron overload. J. Magn. Reson. Imaging 23: 662-668.
39. Ramazzotti, A., A. Pepe, V. Positano, et al. 2009. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. J. Magn. Reson. Imaging 30: 62-68.
40. Ramazzotti,A.,A.Pepe,V. Positano, et al. 2008. Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. Hemoglobin 32: 97-107.